825 related articles for article (PubMed ID: 28319068)
1. Iron addiction: a novel therapeutic target in ovarian cancer.
Basuli D; Tesfay L; Deng Z; Paul B; Yamamoto Y; Ning G; Xian W; McKeon F; Lynch M; Crum CP; Hegde P; Brewer M; Wang X; Miller LD; Dyment N; Torti FM; Torti SV
Oncogene; 2017 Jul; 36(29):4089-4099. PubMed ID: 28319068
[TBL] [Abstract][Full Text] [Related]
2. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
Brard L; Granai CO; Swamy N
Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
[TBL] [Abstract][Full Text] [Related]
3. Linoleic Acid-Glucosamine Hybrid for Endogenous Iron-Activated Ferroptosis Therapy in High-Grade Serous Ovarian Cancer.
Chen Y; Liao X; Jing P; Hu L; Yang Z; Yao Y; Liao C; Zhang S
Mol Pharm; 2022 Sep; 19(9):3187-3198. PubMed ID: 35939328
[TBL] [Abstract][Full Text] [Related]
4. Sodium molybdate inhibits the growth of ovarian cancer cells via inducing both ferroptosis and apoptosis.
Mao G; Xin D; Wang Q; Lai D
Free Radic Biol Med; 2022 Mar; 182():79-92. PubMed ID: 35219846
[TBL] [Abstract][Full Text] [Related]
5. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.
Isobe A; Sawada K; Kinose Y; Ohyagi-Hara C; Nakatsuka E; Makino H; Ogura T; Mizuno T; Suzuki N; Morii E; Nakamura K; Sawada I; Toda A; Hashimoto K; Mabuchi S; Ohta T; Morishige K; Kurachi H; Kimura T
PLoS One; 2015; 10(2):e0118080. PubMed ID: 25658637
[TBL] [Abstract][Full Text] [Related]
7. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of ZNF217 promotes prostate cancer growth by restraining ferroportin-conducted iron egress.
Jiang X; Zhang C; Qi S; Guo S; Chen Y; Du E; Zhang H; Wang X; Liu R; Qiao B; Yang K; Zhang Z; Xu Y
Oncotarget; 2016 Dec; 7(51):84893-84906. PubMed ID: 27768596
[TBL] [Abstract][Full Text] [Related]
10. Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress.
Chen Y; Zhang Z; Yang K; Du J; Xu Y; Liu S
Oncogene; 2015 Jul; 34(29):3839-47. PubMed ID: 25284586
[TBL] [Abstract][Full Text] [Related]
11. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
12. New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases.
Zhan S; Yung MMH; Siu MKY; Jiao P; Ngan HYS; Chan DW; Chan KKL
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499591
[TBL] [Abstract][Full Text] [Related]
13. Gene regulatory networking reveals the molecular cue to lysophosphatidic acid-induced metabolic adaptations in ovarian cancer cells.
Ray U; Roy Chowdhury S; Vasudevan M; Bankar K; Roychoudhury S; Roy SS
Mol Oncol; 2017 May; 11(5):491-516. PubMed ID: 28236660
[TBL] [Abstract][Full Text] [Related]
14. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer.
Fujisawa T; Joshi BH; Puri RK
Int J Cancer; 2012 Jul; 131(2):344-56. PubMed ID: 21858811
[TBL] [Abstract][Full Text] [Related]
15. Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo.
Morita T; Shibata K; Kikkawa F; Kajiyama H; Ino K; Mizutani S
Int J Cancer; 2004 Apr; 109(4):525-32. PubMed ID: 14991573
[TBL] [Abstract][Full Text] [Related]
16. Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment.
Gullbo J; Fryknäs M; Rickardson L; Darcy P; Hägg M; Wickström M; Hassan S; Westman G; Brnjic S; Nygren P; Linder S; Larsson R
Biochem Pharmacol; 2011 Jul; 82(2):139-47. PubMed ID: 21531212
[TBL] [Abstract][Full Text] [Related]
17. A Systems Biology Approach to Understanding the Pathophysiology of High-Grade Serous Ovarian Cancer: Focus on Iron and Fatty Acid Metabolism.
Konstorum A; Lynch ML; Torti SV; Torti FM; Laubenbacher RC
OMICS; 2018 Jul; 22(7):502-513. PubMed ID: 30004845
[TBL] [Abstract][Full Text] [Related]
18. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
[TBL] [Abstract][Full Text] [Related]
19. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
20. Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo.
Gao M; Ma Y; Bast RC; Li Y; Wan L; Liu Y; Sun Y; Fang Z; Zhang L; Wang X; Wei Z
Med Oncol; 2016 Jul; 33(7):73. PubMed ID: 27277757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
